9:22 AM
Leo Group India
| ||
| K-V Pharmaceutical Loses FDA Lawsuit Over Makena Drug Bloomberg "The central issue for K-V Pharmaceutical, in its several court actions regarding MakenaR, has always been to ensure that pregnant women have access to MakenaR, the only drug approved by the Food and Drug Administration for their condition," Herrling ... See all stories on this topic » | ||
| Notices to pharma cos for non-payment of service tax: Govt Financial Express "Show cause notices have been issued to such manufacturers (of pharmaceutical products) for recovery of service tax invoking deterrent penalties and interest," Minister of State for Chemicals and Fertilisers, Srikant Kumar Jena informed the Rajya Sabha. See all stories on this topic » | ||
| Cipla has not infringed F Hoffman La-Roche's patent cancer drug: High Court Economic Times NEW DELHI: The Delhi High Court today held that Indian pharmaceutical major Cipla has not infringed upon the patent right of Swiss drug company F Hoffman La-Roche on a cancer drug. Justice Manmohan Singh said Roche's patented drug Erlotinib ... See all stories on this topic » | ||
| Jazz Pharmaceuticals (NASDAQ:JAZZ) Inks Deal With Meda to Sell Women's ... eStocksDaily Jazz Pharmaceuticals plc (NASDAQ:JAZZ), which combined with Azur Pharma in January and moved to Ireland, is vending its women's health business to specialty pharmaceutical corporation Meda in a $95 million cash deal so that it can focus on its major ... See all stories on this topic » | ||
| Teva sues Perrigo over patents Detroit Free Press Teva Branded Pharmaceutical Products R&D of Horsham, Pa., contends that Allegan-based Perrigo is planning to market its version of the albuterol sulfate aerosol inhaler before the patents expire in 2017 and 2023, according to federal court papers filed ... See all stories on this topic » | ||
| FDA delays pharmaceutical sales approval of Salix's HIV-related diarrhea drug MedReps However, the North Carolina-based company recently announced that federal officials have delayed any decision on the immediate pharmaceutical sales of the new treatment, crofelemer, until the end of the first quarter of 2013. Bill Forbes, executive ... See all stories on this topic » |
Tip: Use quotes ("like this") around a set of words in your query to match them exactly. Learn more.
Delete this alert.
Create another alert.
Manage your alerts.
0 comments:
Post a Comment